NCT02357654 GnRH for Luteal Support in IVF/ICSI/FET Cycles
| NCT ID | NCT02357654 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University Reproductive Associates |
| Condition | Infertility |
| Study Type | INTERVENTIONAL |
| Enrollment | 350 participants |
| Start Date | 2015-11 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 350 participants in total. It began in 2015-11 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .
Eligibility Criteria
Inclusion Criteria: * women undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years old. Exclusion Criteria: * day 3 transfers
Contact & Investigator
Peter G McGovern, MD
PRINCIPAL INVESTIGATOR
Rutgers University
Frequently Asked Questions
Who can join the NCT02357654 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT02357654 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT02357654 currently recruiting?
Yes, NCT02357654 is actively recruiting participants. Contact the research team at mcgovepg@gmail.com for enrollment information.
Where is the NCT02357654 trial being conducted?
This trial is being conducted at Hasbrouck Heights, United States.
Who is sponsoring the NCT02357654 clinical trial?
NCT02357654 is sponsored by University Reproductive Associates. The principal investigator is Peter G McGovern, MD at Rutgers University. The trial plans to enroll 350 participants.